Abstract
The promyelocytic leukemia zinc-finger protein (PLZF) is a transcriptional repressor. To investigate the role of PLZF in the regulation of cytoadhesion molecules involved in the mobilization of hemopoietic cells, we have analysed PLZF and very late antigen 4 (VLA-4) expression in normal and leukemic cells. In hematopoiesis, we found a negative correlation between PLZF and VLA-4 expression, except for the megakaryocytic lineage. In contrast, we observed a positive correlation between PLZF and VLA-4 expression in a panel of acute myeloid leukemia (AML) samples. In K562 cells expressing PLZF (K562-PLZF), we found that the expression of VLA-4 and c-kit was downmodulated. We have investigated the possibility for VLA-4 or the c-kit receptor to be direct target genes of PLZF in K562-PLZF cells and identified a PLZF DNA-binding site within the VLA-4 promoter. Furthermore, decrease in VLA-4 expression was associated with loss of adhesion on fibronectin-coated plates, which promotes drug-induced apoptosis of K562-PLZF cells. Our findings indicate that VLA-4 is a potential target gene of PLZF. However, in primary AMLs the control of PLZF on VLA-4 expression is lost. Altogether, we suggest that VLA-4 modulation by PLZF may represent an important step in the control of normal and leukemic cell mobilization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ball H, Melnick A, Shaknovich R, Kohanski R, Licht JD . (1999). Nucleic Acids Res 27: 4106–4113.
Barna M, Hawe N, Niswander L, Pandolfi PP . (2000). Nat Genet 25: 166–172.
Bendall LJ, Makrynikola V, Hutchinson A, Bianchi AC, Bradstock KF, Gottlieb DJ . (1998). Leukemia 12: 1375–1382.
Buaas FW, Kirsh AL, Sharma M, McLean DJ, Morris JL, Griswold MD et al. (2004). Nat Genet 36: 647–652.
Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z et al. (2004). Oncogene 23: 8777–8784.
Costoya JA, Hobbs RM, Barna M, Cattoretti G, Manova K, Sukhwani M et al. (2004). Nat Genet 36: 653–659.
Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T . (1997). Blood 90: 4779–4788.
Davies JM, Hawa N, Kabarowski J, Huang QH, Zhu J, Brand NJ et al. (1999). Oncogene 18: 365–375.
Felicetti F, Bottero L, Mattia G, Labbaye C, Alvino E, Peschle C et al. (2004). Oncogene 23: 4567–4576.
Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P et al. (1995). Blood 86: 1661–1670.
Gabbianelli M, Sargiacomo M, Pelosi E, Testa U, Isacchi G, Peschle C . (1990). Science 249: 1561–1564.
Gazitt Y . (2004). Leukemia 18: 1–10.
Gazitt Y, Akay C . (2004). Stem Cells 22: 65–73.
Guerriero R, Testa U, Gabbianelli M, Mattia G, Montesoro E, Macioce G et al. (1995). Blood 86: 3725–3736.
Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S et al. (1999). Blood 94: 3737–3747.
Kapur R, Cooper R, Zhang L, Williams DA . (2001). Blood 97: 1975–1981.
Krug U, Ganser A, Koeffler HP . (2002). Oncogene 21: 3475–3495.
Labbaye C, Quaranta MT, Pagliuca A, Militi S, Licht JD, Testa U et al. (2002). Oncogene 21: 6669–6679.
Labbaye C, Valtieri M, Grignani F, Puglisi R, Luchetti L, Masella B et al. (1999). Oncogene 18: 3529–3540.
Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R . (2005). Stem Cells 23: 16–43.
Livak KL, Schmittgen TD . (2001). Methods 25: 402–408.
Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. (2003). Nat Med 9: 1158–1165.
McConnell MJ, Chevalier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM et al. (2003). Mol Cell Biol 24: 9375–9388.
Melnick A, Licht JD . (1999). Blood 93: 3167–3215.
Mossuz P, Schweitzer A, Molla A, Berthier R . (1997). Br J Haematol 98: 819–827.
Papayannopoulou T, Priestley GV, Nakamoto B . (1998). Blood 91: 2231–2239.
Parrado A, Noguera ME, Delmer A, McKenna S, Davies J, Le Gall I et al. (2000). Hematol J 1: 15–27.
Rosen GD, Birkenmeier TM, Dean DC . (1991). Proc Natl Acad Sci USA 88: 4094–4098.
Seftor RE . (1998). Am J Pathol 153: 1347–1351.
Ward JO, McConnell MJ, Carlile GW, Pandolfi PP, Licht JD, Freedman LP . (2001). Blood 98: 3290–3300.
Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA . (1997). J Exp Med 185: 313–323.
Acknowledgements
We thank G Loreto for the preparation of the figures. This work was supported by institutional grants from the Italian Ministry of Health to CL and UT, Associazione Italiana per la Ricerca sul Cancro (AIRC) to RF, and Italy National Grants (Progetto Oncotecnologico, Programma Nazionale Cellule Staminali) to CP.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quaranta, M., Spinello, I., Testa, U. et al. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells. Oncogene 25, 399–408 (2006). https://doi.org/10.1038/sj.onc.1209060
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209060
Keywords
This article is cited by
-
Comprehensive bioinformatics analyses reveal immune genes responsible for altered immune microenvironment in intervertebral disc degeneration
Molecular Genetics and Genomics (2022)
-
PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis
Oncogene (2009)
-
A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis
Nature Cell Biology (2008)
-
The BTB–zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions
Nature Immunology (2008)